Stigmasterol mitigates estrogen-deficiency-induced osteoporosis through inhibition of phosphorylated p65 and MAPK signaling pathways

Stigmasterol mitigates estrogen-deficiency-induced osteoporosis through inhibition of phosphorylated p65 and MAPK signaling pathways

BackgroundOsteoporosis is a pervasive bone metabolic disorder characterized by the progressive degeneration of bone microstructure. Osteoclasts are playing a pivotal role in bone remodeling and resorption. Consequently, modulating osteoclast activity, particularly curbing their overactivation, has b...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiangqiang Zhao, Xingling Chen, Bin Mai, Feihong Che, Zhen Zhang, Pan Kang, Chengyu Hou, Lu Lu, Liangliang Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pharmacology
Subjects:
stigmasterol
post-menopausal osteoporosis
NF-κB signaling pathway
MAPK signaling pathway
osteoclastic differentiation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1527494/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1527494/full

Similar Items